BridgeMD
New treatment option for Lateral Patellofemoral Dislocation Closed Traumatic
Official title MPFLR With Fascia Lata Allograft, Based on Isometry Assessment + Elmslie-Trillat TTO
ClinicalTrials.gov ID: NCT05868434
What this study is testing
- What it's testing
- The aim of this study is to assess outcomes of MPFLR With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Lateral patellar dislocation with subsequent instability
- Failure of non-operative treatment
You likely can't join if
- Active inflammation of the knee;
- Previous surgeries on the patellofemoral joint;
- Fractures around the knee
The study team makes the final eligibility decision.
Where it's taking place
- Bełchatów, Łódź Voivodeship, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bełchatów, Łódź Voivodeship, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.